JBIO

DEFA14A - Jade Biosciences, Inc. (0001798749) (Filer)

SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has closed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $15.00 per share. The gross proceeds to Jade from the offering, before deducting the underwriting discounts and commissions and other off

8-K - Jade Biosciences, Inc. (0001798749) (Filer)

424B5 - Jade Biosciences, Inc. (0001798749) (Filer)

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $15.00 per share. The gross proceeds to Jade from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $150.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering

424B5 - Jade Biosciences, Inc. (0001798749) (Filer)

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in a proposed underwritten public offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering are being offered by Jade. In addition, Jade intends to grant

8-K - Jade Biosciences, Inc. (0001798749) (Filer)

~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect observed to be faster, deeper, and more durable than with first-generation anti-APRIL or dual APRIL/BAFF agentsJADE101 was well-tolerated across all evaluated dosesPhase 2 clinical trial in patients with IgA nephropathy underway, with interim clinical data expected in 2027Phase 3 registrational trial expected to be initiated in the first half of 2027Company to host a webcast and conference call today at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE

SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET to discuss results from the ongoing Phase 1 healthy volunteer study of JADE101. The data are expected to define the dosing strategy and further characterize JADE101's clinical profile as a potentially differentiated, disease-modifying anti–A Proliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A n

Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201 preclinical data demonstrated dose-dependent BAFF-R occupancy, an extended half-life, and sustained B cell depletion in non-human primates SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the first participant has been dosed in a first-in-human (FIH) Phase 1 clinical trial of

Interim Phase 2 JADE101 data are expected in 2027 SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that the first participant has been dosed in JUNIPER, the Company's Phase 2 trial evaluating JADE101 in participants with immunoglobulin A nephropathy (IgAN). JADE101 is designed with ultra-high binding affinity to selectively block APRIL, a key driver of pathogenic IgA production in IgAN, a chronic autoimmune disease that frequently affects young adults and can lead to end-

EFFECT - Jade Biosciences, Inc. (0001798749) (Filer)

EFFECT - Jade Biosciences, Inc. (0001798749) (Filer)

424B3 - Jade Biosciences, Inc. (0001798749) (Filer)

SCHEDULE 13G/A - Jade Biosciences, Inc. (0001798749) (Subject)

S-8 - Jade Biosciences, Inc. (0001798749) (Filer)

S-3 - Jade Biosciences, Inc. (0001798749) (Filer)

S-3 - Jade Biosciences, Inc. (0001798749) (Filer)

424B3 - Jade Biosciences, Inc. (0001798749) (Filer)

424B3 - Jade Biosciences, Inc. (0001798749) (Filer)

10-Q - Jade Biosciences, Inc. (0001798749) (Filer)

8-K - Jade Biosciences, Inc. (0001798749) (Filer)

DEFA14A - Jade Biosciences, Inc. (0001798749) (Filer)

DEF 14A - Jade Biosciences, Inc. (0001798749) (Filer)